Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.57 |
| ▸ | MET | P08581 | 9/20 | 0.57 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733490 | 0.84 | MET (0.61) | KDRMET | |
| SCHEMBL13860941 | 0.79 | KDR (0.70) | KDRMETAXLBRAFRAF1 | |
| SCHEMBL16082697 | 0.78 | KDR (0.62) | KDRMETAXLBRAFRAF1 | |
| SCHEMBL2742559 | 0.77 | MET (0.61) | KDRMETAXLMERTK | |
| SCHEMBL13861046 | 0.77 | KDR (0.64) | KDRMETBRAFRAF1 | |
| SCHEMBL198191 | 0.77 | KDR (0.59) | KDRMETAXLBRAFRAF1 | |
| SCHEMBL4337595 | 0.77 | KDR (0.76) | KDRMETAXLBRAFRAF1 | |
| SCHEMBL13860924 | 0.76 | KDR (0.65) | KDRMETBRAFRAF1 | |
| SCHEMBL4325466 | 0.76 | KDR (0.65) | KDRMETBRAFRAF1 | |
| SCHEMBL13860908 | 0.76 | KDR (0.58) | KDRMETAXLBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | KDR 746/4885MET 545/4885AXL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.